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ABSTRACT
Objectives: To evaluate the predictive value of preoperative CA125 in extra-uterine disease and its association with poor 
prognostic factors in endometrioid-type endometrial cancer (EC).
Material and methods: A total of 423 patients with pathologically proven endometrioid-type EC were included in the 
study. The association between preoperative CA125 level and surgical–pathological factors was evaluated. The conventional 
cut-off value was defined as 35 IU/mL.
Results: A high CA125 level ( > 35 IU/mL) was significantly associated with all of the studied poor prognostic factors, 
except grade. The risk of lymph node metastasis (LNM) increased from 15.9% to 45.7% when CA125 level was > 35 IU/mL 
(p < 0.05). The optimal cut-off value for the prediction of LNM in patients aged > 50 years was determined to be 16 IU/mL 
(sensitivity, specificity, positive predictive value, and negative predictive value were 71%, 60%, 35%, and 87%, respectively.)
Conclusions: Preoperative CA125 level was significantly related with the extent of the disease and LNM. The age-depend-
ent cut-off level of CA125 can improve the prediction of LNM in endometrioid-type EC. For older patients, CA125 level 
of > 16 IU/ml could be used to predict LNM. However, further studies are needed to evaluate the appropriate cut-off level 
of CA125 for younger patients.
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INTRODUCTION
Endometrial cancer (EC) is the most common gyneco-
logical malignancy in women [1]. Eighty-five percent of EC 
is of the endometrioid-type [2]. Even though the Cancer 
Committee of International Federation of Obstetricians and 
Gynecologists (FIGO) continues to recommend extended 
surgical staging in EC, necessity of routine lymphadenectomy 
still remains controversial [3]. It may be possible to provide 
information regarding the risk of lymph node metastases 
(LNM) or necessity of extended surgical staging of patients 
before surgery, which may be helpful in informed decision.
Assessment of preoperative CA125 has been found to 
be clinically useful in EC. A high level of CA125 has been 
associated with deep myometrial invasion, extra-uterine 
spread, LNM, and advanced stage of EC [4, 5]. Furthermore, 
different cut-off values of CA125 with regard to each of the 
poor prognostic factor were identified [6–8]. In some stud-
ies, it was revealed that the cut-off values of CA125 for LNM 
prediction changes according to age groups [4, 9]. However, 
the cut-off values of CA125 that predict the spread of dis-
ease, LNM, or necessity of lymphadenectomy still remains 
controversial. 
Objectives
The main purpose of this study is to evaluate the role of 
preoperative CA125 levels and to determine the age-strat-
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ified cut-off levels for predicting the extent of the disease 
and LNM in endometrioid-type EC patients.
MATERIAL AND METHODS
The data of 534 patients with epithelial EC who under-
went at least a total abdominal hysterectomy and bilateral 
salpingo-oophorectomy between January 1993 and May 
2013 in our clinic and whose CA125 level was known were re-
viewed. Data were obtained from the electronic database of 
a gynecological oncology clinic as well as patient files. Among 
the 534 patients, 26 patients with secondary primary malig-
nancy and 85 patients with non-endometrioid-type EC were 
excluded. Finally, the study included 423 patients who had 
endometrioid-type EC. Institutional review board approval 
was obtained before the study (2016; 204/16).
In our clinic, a frozen section (FS) is routinely utilized 
for patients with EC and staging surgery is performed for 
the patients whose FS analysis revealed non-endometrioid 
adenocarcinoma, FIGO grade 2 or 3 disease, myometrial in-
vasion depth of ≥ 1/2, cervical involvement, and tumor size 
of  > 2 cm. Furthermore, patients with a preoperative diag-
nosis of FIGO grade 3 disease or high-risk cell type undergo 
staging surgery directly. Staging surgery typically involves 
total abdominal hysterectomy, bilateral salpingo-oopho-
rectomy, systematic pelvic-paraaortic lymphadenectomy, 
omentectomy, and cytologic sampling. Lymphadenectomy 
was performed in most of the patients by skeletonizing both 
pelvic and paraaortic regions. Nevertheless, some patients 
were treated by sampling the suspicious lymph nodes as 
per the surgeon’s discretion, especially based on patient 
characteristics such as high risk of comorbidity and mor-
bid obesity. Because patients with positive lymph nodes 
were evaluated, patients who had undergone lymph node 
sampling were also included in the study. Bilateral pelvic 
lymphadenectomy was performed to complete skeletoniza-
tion, in which case, all lymphatic tissues were present around 
the common, external, and internal iliac vessels as well as 
in the obturator fossa that was removed after visualiza-
tion of the obturator nerve. The superior surgical dissection 
margin for pelvic nodes was the aortic bifurcation, and the 
anterior distal surgical dissection margin was the circum-
flex iliac vein. The presacral lymphatic tissue was harvested 
separately. The upper limit of paraaortic lymphadenectomy 
was renal veins. In case of intraoperative identification of 
a macroscopic disease, cytoreductive surgical techniques 
are used in addition to staging surgery. Patients were staged 
according to FIGO 2009 surgical staging criteria of EC [10]. 
Tumor size was described as the largest diameter of the 
tumor present in the uterus. 
Blood samples were taken from the patients just be-
fore surgery for analyzing CA125 levels. CA125 levels were 
measured using enzyme immune-radiometric assay with 
monoclonal antibody (ELSA-CA 125 II; CIS Bio International, 
Filiale de Schering S.A., France), and the conventional cut-off 
value was defined as 35 IU/mL (≤ 35 IU/mL vs. > 35 IU/mL).
Patients that had complete clinical response to initial 
treatment were followed-up every 3 months for the first 
2 years, semi-annually for the next 3 years, and annually 
thereafter. Pelvic examination, abdomino-pelvic ultrasonog-
raphy, complete blood count, and blood chemistry were 
performed at every follow-up visit. Follow-up chest X-ray 
was performed yearly, but in cases of clinical suspicion it was 
used as needed. Thoracic and/or abdominal computerized 
tomography was also performed as needed. CA125 level was 
tested during the follow-up, even though it is not checked 
on a routine basis. Time from initial surgery to death or 
the last contact was defined as median follow-up time. 
Disease-free survival (DFS) was defined as the time period 
from initial surgery to recurrence of disease.
In the univariate analysis, the association between pre-
operative level of CA125 and surgical-pathological factors 
were evaluated by using chi-square test for categorical vari-
ables and by using ANOVA test for continuous variables. To 
define age-dependent CA125 cut-off values for predict-
ing surgical and pathological factors, the patients in the 
study group were divided into two age-based groups 
(≤ 50 vs. > 50 years). This cut-off age was considered be-
cause of the mean menopausal age in our population [11]. 
Receiver operating characteristic (ROC) curve was used to 
define the age-related optimal preoperative CA125 level 
for LNM prediction. Disease-free survival analysis on cat-
egorical variables was performed using the Kaplan-Meier 
method, and significant differences between groups 
were identified using the log-rank test. The factors having 
a p value < 0.25 in the univariate analysis were included in 
the multivariate analysis. The multivariate analysis model 
was created using the variables, which were not inter-relat-
ed, and this analysis was performed using the Cox propor-
tional hazards model. Statistical Package for Social Sciences 
(SPSS; SPSS Inc., Chicago IL, USA), version 17.0, software 
was used for statistical analysis. The cut-off for statistical 
significance was set at a p value of < 0.05.
RESULTS
The median age of the study group was 56.7 years 
(range: 29–83). The median tumor size was 42.6 mm (range; 
10–130 mm). Detailed surgical and pathological findings 
are shown in Table 1. Lymphadenectomy was performed 
on 246 patients and the median number of removed lymph 
nodes was 45 (range; 5–122). 
The mean preoperative CA125 level was 40.3 IU/mL in 
the entire cohort. CA125 level was significantly higher in 
patients who had advanced stage of disease, high-grade tu-
mor, deep myometrial invasion, uterine serosal involvement, 
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lympho-vascular space invasion (LVSI), cervical invasion, 
omental metastasis, large tumor size, and LNM (Tab. 2). The 
mean CA125 level in patients with stage IA was 22.2 IU/mL. 
Although higher CA125 levels are associated with advanced 
stage, among the patients with stage IA disease, CA125 level 
was > 100 IU/mL in 2.2%, > 50 IU/mL in 10%, and > 35 IU/mL 
in 14% patients. The lymphatic involvement site was not 
related with CA125 level (stage IIIC1 vs. IIIC2: 56.4 IU/mL 
vs. 77.9 IU/mL, respectively; p = 0.454).
In the entire study group, high CA125 level (> 35) signifi-
cantly predicted advanced stage of disease, deep myometrial 
invasion, LVSI, uterine serosal involvement, cervical invasion, 
adnexal involvement, positive peritoneal cytology, omental 
metastasis, and LNM (Tab. 3). The likelihood of LNM increased 
from 15.9% to 45.7% if the CA125 level was > 35 IU/mL. 
The CA125 level that predicted surgical prognostic fac-
tors changed with age. The predictive value of the conven-
tional cut-off level for surgical prognostic factors in patients 
aged > 50 years was similar to that for the whole group, while 
CA125 level did not predict omental and LNM in patients 
aged ≤ 50 years (Tab. 3). LNM was predicted in 15% of older 
patients (> 50 years) with a CA125 level of ≤ 35 IU/mL, whereas 
it was determined in 48% of the older patients with CA125 lev-
el > 35 IU/mL (p < 0.0001). In contrast, in younger patients, LNM 
prediction rates were 21% and 40%, respectively (p = 0.124). 
In younger patients (≤ 50 years) who underwent lym-
phadenectomy, the data on preoperative CA125 levels were 
insufficient to define the cut-off values, and the discrimina-
tory power for LNM was low; the area under the curve value 
was 0.656 (95% confidence interval: 0.481–0.831; p = 0.077) 
(Fig. 1). However, in older patients (> 50 years) with lym-
phadenectomy, preoperative CA125 level was predictable 
for LNM and area under the curve value was 0.695 (95% 
confidence interval: 0.602–0.787; p < 0.0001) (Fig. 2). In 
this group, the optimal preoperative CA125 cut-off value 
for predicting LNM was 16 IU/mL. In 43% of the patients 
aged > 50 years, CA125 level was > 16 IU/mL. LNM was ob-
served in 13% and 35% of the patients with a CA125 level 
of ≤ 16 IU/mL and > 16 IU/mL, respectively (p < 0.0001). The 
sensitivity, specificity, positive predictive value (PPV), and 
negative predictive value (NPV) of this level for LNM predic-
tion were 71%, 60%, 35%, and 87%, respectively.
Sixteen patients were not included in the recurrence 
analysis because of lost to follow-up after undergoing initial 
surgery. The median follow-up period of 407 patients was 
44 months (range: 1–240 months). In this period, recur-
rence was detected in 49 patients (11.6%). In the whole 
group, the median CA125 level in patients who experienced 
a recurrence was higher than that in patients who did not 
experience recurrence (respectively, 92.1 IU/mL vs. 34 IU/mL; 
p < 0.0001). The conventional cut-off level predicted re-
currence. Recurrence developed in 22.8% and 8.9% of the 
patients with CA125 levels of ≥ 35 IU/mL and < 35 IU/mL, 
respectively (p < 0.0001). However, this association was 
not observed in the patients with earlier stage of the dis-
ease. In the patients with FIGO stage I and II disease, recur-
rence developed in 9.4% and 4.5% of the patients with 
CA125 levels of ≥ 35 IU/mL and < 35 IU/mL, respectively 
(p = 0.139). None of the patients with FIGO stage IA dis-
Table 1. Patients’ surgical and pathologic characteristics
Characteristics n %
2009 FIGO stage
IA 272 64.3
IB 52 12.3
II 7 1.7
IIIA 11 2.6
IIIB – –
IIIC1 21 5
IIIC2 29 6.9
IVA 5 1.2
IVB 26 6.1
FIGO grade
1 230 54.4
2 120 28.4
3 68 16.1
Not reported 2 1.2
Depth of myometrial 
invasion
No invasion 54 12.8
< 1/2 240 56.7
≥ 1/21 110 26
Uterine serosal invasion 13 3.1
Not reported 6 1.4
Cervical invasion
Negative 365 86.3
Glandular 15 3.5
Stromal 37 8.7
Not reported 6 1.4
Lymphovascular space 
invasion
Negative 276 65.2
Positive 108 25.5
Not reported 39 9.2
Peritoneal cytology
Negative 388 91.7
Positive 21 5
Not reported 14 3.3
Adnexal metastasis
Negative 385 91
Positive 33 7.8
Not reported 5 1.2
Omental metastasis
Negative 379 89.6
Positive 21 5
Not reported 23 5.4
Lymphatic metastasis2
Negative 186 75.6
Positive 60 24.4
1 — except for uterine serosal invasion; 2 — lymphadenectomy performed 
to 246 patients
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Table 2. Associations between preoperative CA125 level and clinical, surgical, pathologic features in endometrioid type endometrial cancer
Factors Mean Median (Range) p value
Age
≤ 57 years 41.3 14 (1–500)
0.676
≥ 58 years 40.9 13.5 (1–1461)
2009 FIGO stage
IA 22.2 13 (1–348)
< 0.0001
IB 33.7 13 (1–289)
II 119 46 (8–391)
IIIA 65.9 24 (3–500)
IIIC1 56.4 23 (1–473)
IIIC2 77.9 29 (1–365)
IVA 52.4 12 (1–195)
IVB 153.9 37 (1–1461)
FIGO grade
Grade 1 30.6 13 (1–500)
0.031Grade 2 44.2 18.5 (1–500)
Grade 3 66.8 13.5 (1–1461)
Depth of myometrial invasion
No invasion 29.4 13.5 (1–348)
< 0.0001< 1/2 23.8 13 (1–391)
≥ 1/21 58.1 20 (1–500)
Uterine serosal invasion
Negative 33.8 14 (1–500)
< 0.0001
Positive 252 48 (1–1461)
Lympho-vascular space invasion
Negative 24 13 (1–348)
< 0.0001
Positive 76.5 20 (1–1461)
Cervical invasion
Negative 29.9 13 (1–500)
< 0.0001Glandular 47.6 23 (2–339)
Stromal 140.3 39 (1–1461)
Adnexal metastasis
Negative 29.6 13 (1–391)
< 0.0001
Positive 169.5 37 (3–1461)
Peritoneal cytology
Negative 30.3 13.5 (1–473)
< 0.0001
Positive 178.1 37 (3–1461)
Omental metastasis
Negative 32.7 14 (1–500)
< 0.0001
Positive 191.9 37 (1–1461)
Tumor size
≤ 40 mm 24.3 11 (1–289)
0.002
≥ 41 mm 91.4 27 (1–1461)
Lymph node metastasis2
Negative 40.3 14 (1–1461)
0.011
Positive 87.2 37 (1–500)
1 — except for uterine serosal invasion; 2 — n = 246 patients underwent lymphadenectomy; p < 0.05 is statistically significant
ease and whose CA125 level was ≥ 100 IU/mL had disease 
recurrence. Five-year DFS of the entire cohort was 85%. In 
univariate analysis, preoperative CA125 level, disease stage, 
and all pathologic features were significantly associated 
with DFS (Tab. 4). In multivariate analysis, both grade and 
conventional CA125 level were independent prognostic 
factors for the risk of recurrence (p = 0.000) (Tab. 5).
DISCUSSION
LNM is one of the most important prognostic factors 
for EC; therefore, the prediction of LNM preoperatively has 
a critical significance in the treatment plan [12]. Preopera-
tive CA125 level is useful as a reliable tumor marker in the 
management of EC [3, 6, 13, 14].
Most studies revealed that CA125 is an independent pre-
dictor of extra-uterine spread in EC [13, 15–17]. There were 
differences in the correlations between high CA125 levels 
and clinical-pathological findings. Chao et al. and Jiang et 
al. determined that high CA125 levels among the patients 
with EC strongly correlated with advanced stage of disease, 
moderate to poor differentiation, deep myometrial inva-
sion, LVSI, positive peritoneal cytology, and LNM, but they 
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did not find any association between CA125 level and the 
type of histology [4, 5]. Dotters et al. found that elevated 
CA125 levels were associated with LVSI and positive peri-
toneal cytology but not with nodal metastases [18]. Kim et 
al. and Chung et al. did not find any statistically significant 
association between grade and higher CA125 levels [6, 8]. 
Furthermore, addition of preoperative CA125 levels to mod-
els including imaging techniques or pathologic features 
significantly increases the rates of LNM prediction [14, 19].
In our study, the mean CA125 level in endometrioid-type 
EC was significantly lower than that in non-endometri-
oid-type EC. Moreover, CA125 level of > 35 IU/mL was sig-
nificantly associated with all of the studied poor prognostic 
factors, except grade. This relationship was elucidated based 
on the following two observations: (1) immunohistochemi-
cal staining revealed that solid and undifferentiated areas of 
EC have low levels of CA125 positivity, therefore high-grade 
tumors may express CA125 less strongly than well-differen-
tiated tumors; (2) serum CA125 level is related to intraperi-
toneal dissemination of cancer cells or dissemination via the 
lympho-vascular system or is associated with bulky nodal 
metastases [18, 20].
The optimal cut-off levels of CA125 still remain contro-
versial. The best cut-off levels for the prediction of poor prog-
nostic factors ranged from 16.2 to 65 IU/mL [6–8, 16]. Hsieh et 
al. showed that the risk of high CA125 level (> 35 IU/mL) was 
7.7 fold higher in patients with positive nodal metastases [7]. 
In our study, LNM probability increased from 15.9% to 45.7% 
when CA125 level was > 35 IU/mL. However, we did not 
find any significant association between CA125 level and 
localization of metastatic lymph node (pelvic or paraaortic).
The best cut-off values for predicting LNM ranged from 
15 to 50 IU/mL [6–9, 16, 18, 21–23]. Koper et al. found that 
while the sensitivity of a cut-off value of 15 IU/mL was higher 
than the conventional cut-off value (35 IU/mL) for identify-
ing patients who would have required a lymphadenectomy 
(53% vs. 17%, respectively), the specificity of this cut-off level 
was lower than that of the conventional cut-off level (76% 
vs. 95%, respectively) [22]. Choi et al. demonstrated that the 
best CA125 cut-off level was 50 IU/mL, with a sensitivity of 
80% and a specificity of 73% for LNM [21]. 
The conventional cut-off CA125 level could predict LNM in 
older patients, but this association was not found in younger 
patients in the present study. Therefore, age-stratified cut-off 
level is important to predict the prognostic factors accurately. 
Yıldız et al. determined that 20 IU/mL cut-off value in the post-
menopausal period was more appropriate to detect LNM, and 
the sensitivity, specificity, PPV, and NPV of this value for LNM 
prediction were 75%, 69.5%, 80.6%, and 84.9%, respectively 
[23]. In a study conducted by Han et al., the cut-off CA125 level 
for predicting LNM in patients aged > 50 years (≥ 28 IU/mL) 
was higher than that in younger patients (≥ 20 IU/mL) [9]. De-
spite this observation, Chao et al. demonstrated that in young 
patients, the cut-off value was higher and they attributed 
this result to other conditions that caused an increase in the 
CA125 level, such as menstruation, endometriosis, and fibroids, 
which were more likely to be noted in young patients [4]. 
In our study, the optimal cut-off value was determined to 
be 16 IU/mL for patients aged > 50 years. The sensitivity, 
specificity, PPV, and NPV of this level for predicting LNM in 
these patients were 71%, 60%, 35%, and 87%, respectively; 
however, the optimal cut-off value could not be determined 
among patients aged < 50 years.
Imaging techniques, such as ultrasonography or 
magnetic resonance imaging, have a limited value to 
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Figure 1. In younger patients (≤ 50 years), the discriminatory power 
of receiver operating characteristic analysis was low for predicting 
lymph node metastases
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patients (> 50 years) that predicted lymph node metastases
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Table 3. Relation between preoperative CA125 level and surgical-pathologic factors in the entire cohort and in groups stratified by age
Factors (% patients)
CA 125 level Age  ≤ 50 years Age > 50 years
CA 125 level CA 125 level
 ≤ 35 IU/mL > 35 IU/mL p value  ≤ 35 IU/mL > 35 IU/mL p value  ≤ 35 IU/mL > 35 IU/mL p value
FIGO stage
I&II 84.5 56.8
 < 0.0001
78.6 53.8
0.017
85.4 56.7
 < 0.0001
III&IV 15.5 43.2 21.4 46.2 14.6 42.3
FIGO grade
Grade 1 57.4 46.8
0.191
58 44
0.461
56 46.3
0.359Grade 2 27.2 34 29 36 27.1 34.3
Grade 3 15.4 19.2 13 20 16.9 19.4
Depth of myometrial invasion
No invasion 14.2 10.3
0.001
17.9 4.3
0.018
13.4 11.3
0.011 < 1/2 63.1 46 65.7 52.2 60.9 43.5
≥ 1/21 22.7 43.7 16.4 43.5 25.6 45.2
Uterine serosal invasion
Negative 98.1 92.6
0.006
98.5 88.5
0.031
98 93.9
0.085
Positive 1.9 7.4 1.5 11.5 2 6.1
Lympho-vascular space invasion
Negative 77.4 51.8
 < 0.0001
82.3 52.2
0.005
74.9 50
 < 0.0001
Positive 22.6 48.2 17.7 47.8 25.1 50
Cervical invasion
Negative 92 72
 < 0.0001
88.2 61.5
 < 0.0001
92.6 75.4
 < 0.0001Glandular 2.8 6.5 5.9 – 2 9.2
Stromal 5.2 21.5 5.9 38.5 5.3 15.4
Adnexal metastasis
Negative 95.1 81.9
 < 0.0001
91.8 69.2
0.008
95.9 86.4
0.004
Positive 4.9 18.1 8.8 30.8 4.1 13.6
Peritoneal cytology
Negative 96.9 87.6
 < 0.0001
96.9 84
0.028
96.7 88.7
0.009
Positive 3.1 12.4 3.1 16 3.3 11.3
Omental metastasis
Negative 97.1 86.5
 < 0.0001
95.3 83.3
0.064
97.4 87.3
0.001
Positive 2.9 14.5 4.7 16.7 2.6 12.7
Lymph node metastasis2
Negative 84.1 54.3
 < 0.0001
79 60
0.124
85 52
 < 0.0001
Positive 15.9 45.7 21 40 15 48
1 — uterine serosal invasion excluded; 2 — n = 246 patients underwent lymphadenectomy, p < 0.05 is statistically significant
determine recurrence in small lesions or to evaluate the 
probability of recurrent disease, but CA125 levels are 
considered to be important in this regard. Nikolaou et al. 
found that the mean preoperative CA125 level of patients 
with recurrence was higher than that of patients without 
recurrence, but the difference was not statistically signifi-
cant (49.4 IU/mL vs. 29.5 IU/mL; p = 0.242) [24]. On the con-
trary, in our study, the patients with recurrence had a sig-
nificantly higher preoperative CA125 level than patients 
without recurrence (respectively, 92.1 IU/mL vs. 34 IU/mL; 
p < 0.0001). Additionally, preoperative CA125 level in-
dependently predicted the development of recurrence. 
The recurrence probability increased by approximately 
three fold when the CA125 level was higher than the 
conventional cut-off level (respectively, 22.8% vs. 8.9%; 
p < 0.0001).
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Table 5. Multi-variant analysis for prediction of recurrence
Hazard Ratio (95% CI)  p value
Factors
CA 125 level (≤ 35 IU/mL vs. 35IU/mL <) 3.03 (1.7–5.3) 0.000*
Grade (I&II vs. III) 3.00 (1.6–5.4) 0.000*
*p < 0.05 is statistically significant
Table 4. Univariant analysis of  clinical-pathologic features and preoperative CA-125 level for disease free survival
Disease Free Survival
5-year [%] p value
Age
 ≤ 50 86
0.732
50 < 84
Preoperative CA 125 level (IU/mL)
 ≤ 35 88
0.000*
35 < 72
Stage
I&II 93
0.000*
III&IV 55
Grade
1 90
0.000*2 83
3 69
Depth of myometrial invasion
No invasion 100
0.000*
 < 1/2 92
 ≥ 1/21 67
Serosal involvement
Negative 86 0.000*
Positive 38
Lympho-vascular space invasion
Negative 93 0.000*
Positive 71
Cervical invasion
Negative 87
0.000*Glandular 90
Stromal 57
Adnexal metastasis
Negative 89 0.000*
Positive 41
Peritoneal cytology
Negative 88 0.000*
Positive 31
Omental metastasis
Negative 87 0.000*
Positive 24
Lymph node metastasis2
Negative 85 0.000*
Positive 56
1 — uterine serosal invasion excluded; 2 — n = 246 patients underwent lymphadenectomy; *p < 0.05 is statistically significant
One of the limitations of this study was its retrospective 
design. Another limitation is that the elevation in other 
tumor marker levels was not evaluated. Nevertheless, this 
is one of the large-scale studies evaluating the preoperative 
CA125 cut-off level for the prediction of LNM and other 
prognostic factors in endometrioid-type EC.
CONCLUSIONS
The preoperative conventional cut-off level of CA125 is 
a useful marker to predict the poor surgical prognostic fac-
tors and risk of recurrence. More importantly, the age-de-
pendent cut-off value of CA125 must be taken into con-
sideration because such cut-off values can improve the 
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prediction of LNM in endometrioid-type EC. The optimal 
cut-off value that can predict LNM in older patients was 
determined to be 16 IU/mL in our study. Preoperative con-
ventional or age-dependent cut-off value of CA125 in EC 
should be considered to refer the patient to a gynecological 
oncology clinic preoperatively. Consequently, the risk of sec-
ond surgery can be decreased. However, further studies are 
needed to evaluate the optimum cut-off level of CA125 in 
younger patients. 
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